Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jan 29, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.9K

Medulloblastoma.

Paul A Northcott1, Giles W Robinson2, Christian P Kratz3

  • 1Department of Developmental Neurobiology, Neurobiology and Brain Tumor Program, St. Jude Children's Research Hospital, Memphis, TN, USA.

Nature Reviews. Disease Primers
|February 16, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

EClinicalMedicine·2026
Same author

Neoadjuvant chemotherapy for pineal region tumors.

Journal of neuro-oncology·2026
Same author

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

The Lancet. Child & adolescent health·2026
Same author

Longitudinal signal changes in the dentato-rubro-olivary pathway of patients with posterior fossa syndrome.

Neuro-oncology practice·2026
Same author

Memantine for Prevention of Cognitive Late Effects in Children and Adolescents Receiving Radiation Therapy for Brain Tumors: A Randomized, Controlled, Pilot Trial.

International journal of radiation oncology, biology, physics·2026
Same author

Silent Verb Generation during fMRI Reveals Post-Radiotherapy Alterations in Cerebellar-Cerebral Language Regions in Patients Treated for Medulloblastoma.

Research square·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
See all related articles
This summary is machine-generated.

Medulloblastoma, a heterogeneous brain tumor, has four main subgroups (WNT, SHH, Group 3, Group 4) requiring tailored treatments. Understanding these subgroups is crucial for personalized therapy and improved patient outcomes.

Area of Science:

  • Neuro-oncology
  • Pediatric oncology
  • Cancer genomics

Background:

  • Medulloblastoma (MB) is a heterogeneous embryonal tumor of the cerebellum.
  • Four main molecular subgroups (WNT, sonic hedgehog (SHH), Group 3, Group 4) exist, each with distinct genetic profiles, age distributions, and prognoses.

Purpose of the Study:

  • To review the epidemiology, molecular pathogenesis, and diagnostic approaches for medulloblastoma.
  • To discuss current management strategies and future directions for targeted therapies based on molecular subgroups.

Main Methods:

  • Review of existing literature on medulloblastoma.
  • Integration of histomorphology, molecular genetics, and imaging for diagnosis.
  • Discussion of surgical, radiological, and chemotherapeutic treatment modalities.

More Related Videos

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

16.8K
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

12.6K

Related Experiment Videos

Last Updated: Jan 29, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.9K
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
06:32

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

16.8K
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
05:10

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

12.6K

Main Results:

  • Medulloblastoma classification is evolving with the incorporation of molecular subgroups into the WHO classification.
  • Subgroup-specific genetic alterations influence disease risk and therapeutic response.
  • Current management involves surgery, radiation, and chemotherapy, with a need for risk-adapted and biology-targeted approaches.

Conclusions:

  • Accurate diagnosis and risk stratification of medulloblastoma require integrating histopathology, molecular genetics, and imaging.
  • Future clinical trials must focus on molecularly driven patient stratification to optimize treatment intensity and target disease biology for improved outcomes.